These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32636502)

  • 1. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
    Robert C; Marabelle A; Herrscher H; Caramella C; Rouby P; Fizazi K; Besse B
    Nat Rev Clin Oncol; 2020 Nov; 17(11):707-715. PubMed ID: 32636502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
    Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
    Mulder EEAP; de Joode K; Litière S; Ten Tije AJ; Suijkerbuijk KPM; Boers-Sonderen MJ; Hospers GAP; de Groot JWB; van den Eertwegh AJM; Aarts MJB; Piersma D; van Rijn RS; Kapiteijn E; Vreugdenhil G; van den Berkmortel FWPJ; Hoop EO; Franken MG; Ryll B; Rutkowski P; Sleijfer S; Haanen JBAG; van der Veldt AAM
    BMC Cancer; 2021 Mar; 21(1):323. PubMed ID: 33765967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
    van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
    Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
    Lim SY; da Silva IP; Adegoke NA; Lo SN; Menzies AM; Carlino MS; Scolyer RA; Long GV; Lee JH; Rizos H
    Mol Cancer; 2024 Oct; 23(1):228. PubMed ID: 39394099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Dimitriou F; Zaremba A; Allayous C; Kähler KC; Gerard CL; Festino L; Schäfer S; Toussaint F; Heinzerling L; Hassel JC; Ascierto PA; Michielin O; Hauschild A; Lebbe C; Livingstone E; Ramelyte E; Cheng PF; Dummer R; Mangana J
    Eur J Cancer; 2021 May; 149():37-48. PubMed ID: 33823361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
    Hossain SM; Ly K; Sung YJ; Braithwaite A; Li K
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients.
    Persa OD; Schatton K; Rübben A; Berking C; Erdmann M; Schlaak M; Mauch C; Steeb T
    J Immunother; 2021 Jul-Aug 01; 44(6):239-241. PubMed ID: 34028389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for advanced melanoma: current situation in Japan.
    Kato J; Uhara H
    Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.
    Hossain SM; Carpenter C; Eccles MR
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
    Squicciarini T; Villani R; Apollonio B; Fucci L; Zambetti M; Rossini M; Pinto R; Tommasi S; De Roma I; Strippoli S; Guida M
    Front Immunol; 2024; 15():1369531. PubMed ID: 38799429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.